secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-07-08T23:59:59+00:00
Accession:  0001297184-22-000036
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar enters $2.2M R&D agreement with related party Hanxin for insulin cell banks
--------------------------------------------------------------------------------

- Agreement with Nanjing Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and provide exclusive worldwide license.
- Total cost capped at ~$2.2M; initial payment ~$0.2M; payments in Chinese yuan.
- Related party: CEO Jack Zhang & Chairman Mary Luo family own majority of Hanxin; approved by independent Audit Committee.
- Agreement term three years; Amphastar owns all title to RCBs and related IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000036/0001297184-22-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000036/amph-20220705x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer